Effects of Per2 overexpression on growth inhibition and metastasis, and on MTA1, nm23-H1 and the autophagy-associated PI3K/PKB signaling pathway in nude mice xenograft models of ovarian cancer

Wang,Zhaoxia; Li,Li; Wang,Yang

doi:10.3892/mmr.2016.5116

Effects of Per2 overexpression on growth inhibition and metastasis, and on MTA1, nm23-H1 and the autophagy-associated PI3K/PKB signaling pathway in nude mice xenograft models of ovarian cancer

Authors:
- Zhaoxia Wang
- Li Li
- Yang Wang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Bank of China Shanxi Branch, Taiyuan, Shanxi 030001, P.R. China
Published online on: April 13, 2016 https://doi.org/10.3892/mmr.2016.5116
Pages: 4561-4568
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the association between Period2 (Per2) and the occurrence and development of ovarian cancer, in addition to evaluating the effect of this gene on the growth and metastasis of ovarian cancer in nude mice xenograft models. The detection of Per2 by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blotting methods at various stages of ovarian cancer in tumor tissue samples was conducted. Nude mice xenograft models of ovarian cancer were constructed using an ovarian cancer cell line and, using a gene transfection technique, exogenous infusion of the recombinant gene, Per2, was performed. To assess for the successful and stable expression of Per2 in the tumor tissue, levels of Per2 expression in the nude mice xenograft models were detected by RT‑qPCR. During the experimental period, the tumor volumes were measured every three days. Two weeks following treatment cessation, the nude mice were sacrificed and the tumor weight and volume were measured. Furthermore, detection of the changes in expression levels of metastasis‑associated gene 1 (MTA‑1) and tumor metastasis suppressor gene, non‑metastasis protein 23‑H1 (nm23‑H1), and the expression change of autophagy‑associated signal transduction pathway, phosphatidylinositol 3‑kinase (PI3K)/protein kinase B (PKB) kinase were analyzed. The findings demonstrated that with ovarian cancer stage development, the expression of Per2 gradually reduced or ceased. In addition, exogenous Per2 was successfully and stably expressed in nude mice tumor tissue samples. Furthermore, in the Per2 overexpression group, MTA‑1 protein expression was significantly reduced when compared with the phosphate‑buffered saline (PBS) control and empty plasmid groups, while nm23‑H1 protein expression was significantly higher when compared with those two groups. The expression levels of PI3K and PKB kinase, which are marker proteins of the autophagy associated signaling pathway PI3K/PKB, were significantly downregulated, when compared with the PBS control and empty plasmid groups (P<0.001). Thus, it was demonstrated that Per2 is closely associated with the development of ovarian cancer, and late‑stage ovarian cancer is associated with Per2 mutation or deletion. Per2 overexpression, via exogenous infusion reduced the ovarian cancer growth rate, which was demonstrated by a significant increase in the tumor inhibition rate. In addition, Per2 may inhibit the expression of MTA‑1 and promote the expression of nm23‑H1 to restrict ovarian tumor growth and metastasis. Finally, it is hypothesized that Per2 affects autophagy by interfering with the PI3K/PKB signaling pathway, causing inhibition of tumor angiogenesis in order to inhibit tumor growth.

View Figures

View References

1	Nasioudis D, Sisti G, Kanninen TT, Holcomb K, Di Tommaso M, Fambrini M and Witkin SS: Epidemiology and outcomes of squamous ovarian carcinoma; a population-based study. Gynecol Oncol. 2016. View Article : Google Scholar
2	Kosary CL: FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973–87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 10:31–46. 1994. View Article : Google Scholar : PubMed/NCBI
3	Jiang J, Xie W and Cao J: Current situation of the therapies of middle-advanced ovarian cancer. Zhong Liu Yao Xue. 3:416–421. 2013.In Chinese.
4	He JR, Gao X and Ren ZF: Global Incidence Patterns of Female Breast and Ovarian Cancers. China Cancer. 3:169–172. 2009.
5	Lou JY, Peng ZL, Zheng Y, Wang H, He B and Wang HJ: Research on human ovarian cancer cell MDR1 gene silenced by siRNA. Sichuan Da Xue Xue Bao Yi Xue Ban. 38:753–755. 2007.In Chinese. PubMed/NCBI
6	Menendez L, Walker D, Matyunina LV, Dickerson EB, Bowen NJ, Polavarapu N, Benigno BB and McDonald JF: Identification of candidate methylation-responsive genes in ovarian cancer. Mol Cancer. 6:102007. View Article : Google Scholar : PubMed/NCBI
7	Tei H, Okamura H, Shigeyoshi Y, Fukuhara C, Ozawa R, Hirose M and Sakaki Y: Circadian oscillation of a mammalian homologue of the Drosophila period gene. Nature. 389:512–516. 1997. View Article : Google Scholar : PubMed/NCBI
8	Shigeyoshi Y, Taguchi K, Yamamoto S, Takekida S, Yan L, Tei H, Moriya T, Shibata S, Loros JJ, Dunlap JC and Okamura H: Light-induced resetting of a mammalian circadian clock is associated with rapid induction of the mPer1 transcript. Cell. 91:1043–1053. 1997. View Article : Google Scholar
9	Jin X, Shearman LP, Weaver DR, Zylka MJ, de Vries GJ and Reppert SM: A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock. Cell. 96:57–68. 1999. View Article : Google Scholar : PubMed/NCBI
10	Reppert SM and Weaver DR: Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol. 63:647–676. 2001. View Article : Google Scholar : PubMed/NCBI
11	Young MW and Kay SA: Time zones: A comparative genetics of circadian clocks. Nat Rev Genet. 2:702–715. 2001. View Article : Google Scholar : PubMed/NCBI
12	Bjarnason GA and Jordan R: Circadian variation of cell proliferation and cell cycle protein expression in man: Clinical implications. Prog Cell Cycle Res. 4:193–206. 2000. View Article : Google Scholar : PubMed/NCBI
13	Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F and Okamura H: Control mechanism of the circadian clock for timing of cell division in vivo. Science. 302:255–259. 2003. View Article : Google Scholar : PubMed/NCBI
14	Panda S, Antoch MP, Miller BH, Su AI, Schook AB, Straume M, Schultz PG, Kay SA, Takahashi JS and Hogenesch JB: Coordinated transcription of key pathways in the mouse by the circadian clock. Cell. 109:307–320. 2002. View Article : Google Scholar : PubMed/NCBI
15	Barbason H, Herens C, Robaye B, Milis G, Sulon J, Bouzahzah B and VanCantfort J: Importance of cell kinetics rhythmicity for the control of cell proliferation and carcinogenesis in rat liver (review). In Vivo. 9:539–548. 1995.PubMed/NCBI
16	Hansen J: Increased breast cancer risk among women who work predominantly at night. Epidemiology. 12:74–77. 2001. View Article : Google Scholar : PubMed/NCBI
17	Lee CC: Tumor suppression by the mammalian Period genes. Cancer Causes Control. 17:525–530. 2006. View Article : Google Scholar : PubMed/NCBI
18	Fu L, Pelicano H, Liu J, Huang P and Lee C: The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 111:41–50. 2002. View Article : Google Scholar : PubMed/NCBI
19	Gery S, Komatsu N, Baldjyan L, Yu A, Koo D and Koeffler HP: The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 22:375–382. 2006. View Article : Google Scholar : PubMed/NCBI
20	Pecorelli S, Benedet JL, Creasman WT and Shepherd JH; FIGO staging of gynecologic cancer; 1994–1997 FIGO committee on Gynecologic Oncology: International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 65:243–249. 1999. View Article : Google Scholar : PubMed/NCBI
21	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
22	Karantanos T, Theodoropoulos G, Pektasides D and Gazouli M: Clock genes: Their role in colorectal cancer. World J Gastroenterol. 20:1986–1992. 2014. View Article : Google Scholar : PubMed/NCBI
23	Chi C, He ZF, Liu Y, Lin XM and Sun CC: Expression and clinical significance of circadian gene Per2 in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 35:129–131. 2013.In Chinese. PubMed/NCBI
24	Yang X, Wood PA, Oh EY, Du-Quiton J, Ansell CM and Hrushesky WJ: Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat. 117:423–431. 2009. View Article : Google Scholar
25	Koyanagi S, Kuramoto Y, Nakagawa H, Aramaki H, Ohdo S, Soeda S and Shimeno H: A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res. 63:7277–7283. 2003.PubMed/NCBI
26	Toh Y, Oki E, Oda S, Tokunaga E, Ohno S, Maehara Y, Nicolson GL and Sugimachi K: Overexpression of the MTA1 gene in gastrointestinal carcinomas: Correlation with invasion and metastasis. Int J Cancer. 74:459–463. 1997. View Article : Google Scholar : PubMed/NCBI
27	Talukder AH, Mishra SK, Mandal M, Balasenthil S, Mehta S, Sahin AA, Barnes CJ and Kumar R: MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions. J Biol Chem. 278:11676–11685. 2003. View Article : Google Scholar : PubMed/NCBI
28	Avtanski DB, Nagalingam A, Kuppusamy P, Bonner MY, Arbiser JL, Saxena NK and Sharma D: Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner. Oncotarget. 6:16396–16410. 2015. View Article : Google Scholar : PubMed/NCBI
29	Marzook H, Deivendran S, Kumar R and Pillai MR: Role of MTA1 in head and neck cancers. Cancer Metastasis Rev. 33:953–964. 2014. View Article : Google Scholar : PubMed/NCBI
30	Bruning A, Blankenstein T, Jückstock J and Mylonas I: Function and regulation of MTA1 and MTA3 in malignancies of the female reproductive system. Cancer Metastasis Rev. 33:943–951. 2014. View Article : Google Scholar : PubMed/NCBI
31	Deng X, Du L, Wang C, Yang Y, Li J, Liu H, Zhang J, Wang L, Zhang X, Li W, et al: Close association of metastasis-associated protein 1 overexpression with increased angiogenesis and poor survival in patients with histologically node-negative gastric cancer. World J Surg. 37:792–798. 2013. View Article : Google Scholar : PubMed/NCBI
32	Martin MD, Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, Allred DC and O'Connell P: Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 95:7–12. 2006. View Article : Google Scholar
33	Cheng CW, Liu YF, Yu JC, Wang HW, Ding SL, Hsiung CN, Hsu HM, Shieh JC, Wu PE and Shen CY: Prognostic significance of cyclin D1, β-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast. Ann Surg Oncol. 19:4129–4139. 2012. View Article : Google Scholar : PubMed/NCBI
34	Zhang H, Zhu X, Li N, Li D, Sha Z, Zheng X and Wang H: miR-125a-3p targets MTA1 to suppress NSCLC cell proliferation, migration, and invasion. Acta Biochim Biophys Sin. 47:496–503. 2015. View Article : Google Scholar : PubMed/NCBI
35	Kawasaki G, Yanamoto S, Yoshitomi I, Yamada S and Mizuno A: Overexpression of metastasis-associated MTA1 in oral squamous cell carcinomas: Correlation with metastasis and invasion. Int J Oral Maxillofac Surg. 37:1039–1046. 2008. View Article : Google Scholar : PubMed/NCBI
36	Gilles AM, Presecan E, Vonica A and Lascu I: Nucleoside diphosphate kinase from human erythrocytes. Structural characterization of the two polypeptide chains responsible for heterogeneity of the hexameric enzyme. J Biol Chem. 266:8784–8789. 1991.PubMed/NCBI
37	Luo S, Wang X and Sun X: The expression and clinical significance of p16 and nm23 in cervical carcinoma. Zhong Guo Shi Yong Fu Ke Yu Chan Ke. 7:421–422. 2004.In Chinese.
38	Utrera-Barillas D, Salcedo-Vargas M, Gariglio-Vidal P, Hernández-Hernández DM, Gutiérrez-Delgado F and Benítez-Bribiesca L: H-ras and Nm23-H1 gene expression and proteolytic activity in squamous cell carcinoma of the uterine cervix. Arch Med Res. 31:172–181. 2000. View Article : Google Scholar : PubMed/NCBI
39	Wu W, Xu H and Deng Z: Expression of nm23H1 and E-cadherin protein in 39 cases of endometrial carcinoma. Zhong Liu Xue Zazhi. 4:322–323. 2006.
40	Ding GF, Li JC and Xu YF: Study on the correlationship between the expression of nm23H1mRNA, TGF-beta1mRNA and tumor metastases, survival rate with prostate cancer. Fen Zi Xi Bao Sheng Wu Xue Bao. 39:544–552. 2006.In Chinese.
41	Nicholson KM and Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
42	Li Q and Zhu GD: Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr Top Med Chem. 2:939–971. 2002. View Article : Google Scholar : PubMed/NCBI
43	Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM and Thompso CB: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64:3892–3899. 2004. View Article : Google Scholar : PubMed/NCBI
44	Kim D, Kim S, Koh H, Yoon SO, Chung AS, Cho KS and Chung J: Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 15:1953–1962. 2001. View Article : Google Scholar : PubMed/NCBI
45	Huang Y, Cai S and Yu S: Relationship between nm23-H1 expression and lymph node metastasis and prognosis in cervical cancer. Zhonghua Fu Chan Ke Za Zhi. 32:718–721. 1997.In Chinese.
46	Utrera-Barillas D, Salcedo-Vargas M, Gariglio-Vidal P, Hernández-Hernández DM, Gutiérrez-Delgado F and Benítez-Bribiesca F: H-ras and nm23-H1 gene expression and proteolytic activity in squamous cell carcinoma of the uterine cervix. Arch Med Res. 31:172–181. 2000. View Article : Google Scholar : PubMed/NCBI
47	Tong Y, Yung LY and Wong YH: Metastasis suppressors nm23H1 and nm23H2 differentially regulate neoplastic transformation and tumorigenesis. Cancer Lett. 361:207–217. 2015. View Article : Google Scholar : PubMed/NCBI